Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-CDK4 Antibody (R3C70)

Catalog #:   RHC90505 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IF, IHC
Accession: P11802
Overview

Catalog No.

RHC90505

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000

Target

Cell division protein kinase 4, PSK-J3, Cyclin-dependent kinase 4, CDK4

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P11802

Applications

ELISA, FCM, IF, IHC

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3C70

Data Image
  • Flow Cytometry
    Flow cytometric analysis of K562 cells using CDK4 mouse mAb (green) and negative control (red).
  • Flow Cytometry
    Flow cytometric analysis of U937 cells using CDK4 mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of Hela cells using CDK4 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using CDK4 mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using CDK4 mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using CDK4 mouse mAb with DAB staining.
References

Antibody-mediated ratiometric delivery of FLT3 and CDK4/6 dual inhibitors for targeted treatment of acute myeloid leukemia., PMID:40482924

Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer., PMID:40449480

Comprehensive advances in HER2-positive and HER2-negative breast cancer: unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes., PMID:40439885

Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study., PMID:40405072

Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast Cancer., PMID:40386501

Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy., PMID:40385566

Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium., PMID:40340127

MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment., PMID:40287441

The treatment of breast cancer in the era of precision medicine., PMID:40269562

Therapy of early breast cancer: current status and perspectives., PMID:40261372

Progressive multifocal leukoencephalopathy during 4 years of Palbociclib for advanced breast cancer with a history of follicular lymphoma patient., PMID:40259166

Desmoplastic small round cell tumor: an update of current management practices., PMID:40254671

Novel Estrogen Receptor - Targeted Therapies in Hormone-Receptor Positive Breast Cancer., PMID:40163189

Long‑term progression‑free survival in HR+/HER2+ advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first‑line maintenance therapy: A case report., PMID:40110580

Efficiency of Fulvestrant Monotherapy After CDK4/6 Inhibitor Exposure: Is This a Viable Choice?, PMID:40075731

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies., PMID:40038334

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer., PMID:40010764

Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis., PMID:40006075

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy., PMID:40005476

Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline., PMID:40002228

First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis., PMID:39969377

Implication of TRPM8, CD47, and CDK4 expressions in hepatocellular carcinoma progression., PMID:39957041

[A Case of a Patient with Hormone-Positive HER2-Negative Breast Cancer Whose Multiple Brain Metastases Disappeared after Abemaciclib Combination Therapy]., PMID:39948886

Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future., PMID:39900320

RANK/RANKL Signaling Pathway in Breast Development and Cancer., PMID:39821032

The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer., PMID:39747865

Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer., PMID:39664178

Ribociclib-Induced Autoimmune Hepatitis: A Case Report., PMID:39559679

Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion., PMID:39534582

Updates in Treatment of HER2-positive Metastatic Breast Cancer., PMID:39520520

Impaired cyclin D3 protein degradation contributes to trastuzumab resistance in HER2 positive breast cancer., PMID:39487929

Current landscape of targeted therapy in esophageal squamous cell carcinoma., PMID:39454516

A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: A review of current and investigational treatment for HR+/Her2- breast cancer., PMID:39433229

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma., PMID:39405335

Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis., PMID:39373732

IMP3, CDK4, MDM2 and β-catenin expression in Enchondroma and Central Chondrosarcoma: Diagnostic and prognostic utility., PMID:39368400

Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer., PMID:39218402

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024., PMID:39184927

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer., PMID:39179659

p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells., PMID:39103548

Systemic Therapy in Breast Cancer., PMID:39013124

Revised Diagnosis From Histiocytic Neoplasm to Optic Chiasm Glioblastoma After Genetic Analysis., PMID:38926909

Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer., PMID:38884028

Case report: Pilomatrix carcinoma with PDL1 expression and CDKN2A aberrant., PMID:38873609

CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer., PMID:38854937

Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments., PMID:38838928

GPR168 functions as a tumor suppressor in mouse melanoma by restraining Akt signaling pathway., PMID:38805406

Current Status and Future Perspectives of Antibody-Drug Conjugates in Hormone Receptor-Positive Breast Cancer., PMID:38791880

The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)., PMID:38779868

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer., PMID:38772169

Datasheet

Document Download

Anti-CDK4 Antibody (R3C70).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-CDK4 Antibody (R3C70) [RHC90505]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only